Wein W - Search Results

1

Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): an AASLC phase II trial. Austrian Association for the Study of Lung Cancer.

Krajnik G, Mohn-Staudner A, Thaler J, Greil R, Schmeikal S, Marhold F, Deutsch J, Preiss P, Malayeri R, Schäfer-Prokop C, Wein W, Huber H, Pirker R. Krajnik G, et al. Among authors: wein w. Ann Oncol. 2000 Aug;11(8):993-8. doi: 10.1023/a:1008370704612. Ann Oncol. 2000. PMID: 11038036 Free article. Clinical Trial.

2

Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial.

Krajnik G, Wein W, Greil R, Marhold F, Mohn-Staudner A, Kummer F, Malayeri R, Zöchbauer-Müller S, Huber H, Pirker R. Krajnik G, et al. Among authors: wein w. Eur J Cancer. 1998 Nov;34(12):1977-80. doi: 10.1016/s0959-8049(98)00235-4. Eur J Cancer. 1998. PMID: 10023326 Clinical Trial.

3

Effective intrahepatic administration of gemcitabine after failure of doxorubicin in metastatic breast cancer.

Malayeri R, Wein W, Zielinski C. Malayeri R, et al. Among authors: wein w. Eur J Cancer. 1997 Dec;33(14):2435. doi: 10.1016/s0959-8049(97)00313-4. Eur J Cancer. 1997. PMID: 9616295 No abstract available.

4

Gemcitabine and vincristine: an effective outpatient regimen with low myelotoxicity for stage IV non-small cell lung cancer.

Zwitter M, Cufer T, Wein W. Zwitter M, et al. Among authors: wein w. Neoplasma. 2001;48(3):200-2. Neoplasma. 2001. PMID: 11583289 Clinical Trial.

5

Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer.

Brodowicz T, Kostler WJ, Möslinger R, Tomek S, Vaclavik I, Herscovici V, Wiltschke C, Steger GG, Wein W, Seifert M, Kubista E, Zielinski CC. Brodowicz T, et al. Among authors: wein w. Breast. 2000 Dec;9(6):338-42. doi: 10.1054/brst.2000.0170. Breast. 2000. PMID: 14965758

6

Delayed addition of deoxycytidine protects normal CD34+ cells against cytotoxicity of gemcitabine without compromising its activity against human leukemic cells.

Tiefenthaler M, Hohla F, Strasser-Wozak E, Bacher N, Mühlmann O, Wein W, Konwalinka G. Tiefenthaler M, et al. Among authors: wein w. Stem Cells. 2003;21(3):266-71. doi: 10.1634/stemcells.21-3-266. Stem Cells. 2003. PMID: 12743321

7

Preprandial vs. postprandial insulin lispro-a comparative crossover trial in patients with Type 1 diabetes.

Schernthaner G, Wein W, Shnawa N, Bates PC, Birkett MA. Schernthaner G, et al. Among authors: wein w. Diabet Med. 2004 Mar;21(3):279-84. doi: 10.1111/j.1464-5491.2004.01132.x. Diabet Med. 2004. PMID: 15008840

8

Postprandial insulin lispro. A new therapeutic option for type 1 diabetic patients.

Schernthaner G, Wein W, Sandholzer K, Equiluz-Bruck S, Bates PC, Birkett MA. Schernthaner G, et al. Among authors: wein w. Diabetes Care. 1998 Apr;21(4):570-3. doi: 10.2337/diacare.21.4.570. Diabetes Care. 1998. PMID: 9571344 Clinical Trial.

9

In vitro studies on the immunosuppressive effect of 2',2'-difluorodeoxycytidine (dFdC) and its metabolite 2',2'-difluorodeoxyuridine (dFdU).

Tiefenthaler M, Hohla F, Irschick E, Strasser-Wozak E, Bacher N, Mühlmann O, Wein W, Konwalinka G. Tiefenthaler M, et al. Among authors: wein w. Immunobiology. 2003;207(2):149-57. doi: 10.1078/0171-2985-00223. Immunobiology. 2003. PMID: 12675273

10

In vitro release of vancomycin and tobramycin from impregnated human and bovine bone grafts.

Winkler H, Janata O, Berger C, Wein W, Georgopoulos A. Winkler H, et al. Among authors: wein w. J Antimicrob Chemother. 2000 Sep;46(3):423-8. doi: 10.1093/jac/46.3.423. J Antimicrob Chemother. 2000. PMID: 10980169

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52 results

Search Page

Filters